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Abstract 
Background: The number of people entering specialist drug treatment for cannabis problems 
has increased considerably in recent years. The reasons for this are unclear, but rising 
cannabis potency could be a contributing factor. 
Methods: Cannabis potency data were obtained from an ongoing monitoring programme in 
the Netherlands. We analysed concentrations of delta-9-tetrahydrocannabinol (THC) from the 
most popular variety of domestic herbal cannabis sold in each retail outlet (2000-2015). 
Mixed effects linear regression models examined time-dependent associations between THC 
and first-time cannabis admissions to specialist drug treatment. Candidate time lags were 0-
10 years, based on normative European drug treatment data. 
Results: THC increased from a mean (95% CI) of 8.62 (7.97, 9.27) to 20.38 (19.09, 21.67) 
from 2000-2004 and then decreased to 15.31 (14.24, 16.38) in 2015. First-time cannabis 
admissions (per 100,000 inhabitants) rose from 7.08 to 26.36 from 2000-2010, and then 
decreased to 19.82 in 2015. THC was positively associated with treatment entry at lags of 0-9 
years, with the strongest association at 5 years, b=0.370 (0.317, 0.424), p<0.0001. After 
adjusting for age, sex and non-cannabis drug treatment admissions, these positive 
associations were attenuated but remained statistically significant at lags of 5-7 years and 
were again strongest at 5 years, b=0.082 (0.052, 0.111), p<0.0001. 
Conclusions: In this sixteen-year observational study, we found positive time-dependent 
associations between changes in cannabis potency and first-time cannabis admissions to drug 
treatment. These associations are biologically plausible, but their strength after adjustment 
suggests that other factors are also important. 
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Introduction 
Cannabis is used by an estimated 183 million people, and accounts for around half of all first-
time admissions to specialist drug treatment worldwide (UNODC, 2016). The number of 
people entering specialist drug treatment for cannabis problems has risen considerably in 
recent years. Across Europe, there was a 53% increase in first-time clients between 2006 and 
2014, and cannabis has now superseded opiates as the primary problem drug (EMCDDA, 
2016). These changes highlight a concerning increase in population markers of burden and 
morbidity attributable to cannabis.  There are no approved pharmacotherapies for the 
treatment of cannabis use disorders, and psychosocial interventions have limited efficacy 
(Curran et al., 2016). The increase in cannabis admissions, alongside a lack of evidence-
based interventions creates a significant challenge for treatment providers (Monaghan et al., 
2016). Clients entering specialist drug treatment with cannabis as a primary problem have 
shown the poorest treatment outcomes at six months (rates of abstinence and reduction in 
use) of all illicit drugs (NDTMS, 2014). 
Interestingly, cannabis-related treatment admissions have continued to rise in some regions 
despite stable or decreasing prevalence of use estimates, including Germany, Spain and the 
UK (UNODC, 2016). There are several possible reasons for this, including changes in 
treatment availability, attitudes towards cannabis, or that cannabis is becoming an 
increasingly harmful substance. The primary psychoactive constituent of cannabis is delta-9-
tetrahydrocannabinol (THC), which has dose-related effects on drug reinforcement, memory 
impairment and psychotic-like symptoms (Curran et al., 2016). Concentrations of THC have 
risen considerably in the US (ElSohly et al., 2016), UK (Potter et al., 2008) and worldwide 
(Cascini et al., 2012) in recent decades. For example, a study of illicit cannabis samples in the 
US (ElSohly et al., 2016) suggested that THC concentrations rose from a mean of 4% in 1995 
to 12% in 2014. More recently, a dramatic rise in potency was reported within two years of 
   4 
 
legal sales in Washington State, where extremely high-potency extracts (~70% THC) now 
comprise around 20% of purchases (Smart et al., 2017).  
 
Use of cannabis products with high concentrations of THC has been linked to poorer mental 
and addiction health outcomes (Chan et al., 2017, Di Forti et al., 2015, Freeman and 
Winstock, 2015, Meier, 2017, Schoeler et al., 2016). A cross-sectional online survey 
(Freeman and Winstock, 2015) found that use of cannabis with high THC content was more 
strongly associated with cannabis dependence than lower potency forms of cannabis. 
Moreover, this association was found to be stronger in younger cannabis users.  A second 
cross-sectional online survey found that use of extremely-high potency cannabis concentrates 
(Butane Hash Oil) was associated with greater physical dependence on cannabis, and this 
association was robust after accounting for possible confounds using both covariate 
adjustment and propensity score matching (Meier, 2017). Prospective studies have reported 
an association between degree of cannabis exposure and transition to cannabis dependence 
(Silins et al., 2014), although not in those who are using cannabis (near) daily at baseline 
(van der Pol et al., 2013a). Naturalistic studies suggest that cannabis users only partially 
adapt their smoking behaviour to differences in cannabis potency (Freeman et al., 2014, van 
der Pol et al., 2014). Taken together, it is plausible that long-term changes in cannabis 
potency could influence cannabis-related harms (including changes in cannabis admissions to 
drug treatment). Although the potential health impacts of increasing cannabis potency have 
been widely acknowledged (Di Forti et al., 2015, ElSohly et al., 2016, EMCDDA, 2016, 
Freeman and Winstock, 2015, McLaren et al., 2008, UNODC, 2016) we are unaware of any 
previous attempts to empirically test associations between changes in cannabis potency and 
population markers of cannabis harms. 
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Effective monitoring of cannabis potency can play a critical role in estimating the potential 
health impact of cannabis use in different regions.  However, high-quality and long-term 
monitoring programmes are extremely rare (Freeman and Swift, 2016). Of those available, 
the Trimbos Institute potency monitor (Niesink et al., 2015, Pijlman et al., 2005) offers the 
highest quality evidence and is the most suitable resource for testing associations between 
changes in potency and cannabis harms. Firstly, cannabis samples are purchased directly at 
the retail level from ‘coffee shops’ using randomised sampling. This method is advantageous 
to other studies utilising cannabis samples from police seizures, which may be biased by law 
enforcement methods (Nguyen and Reuter, 2012), sampling bias, and variation in sample 
degradation during storage (Sevigny, 2013). Secondly, in contrast to linear increases in 
cannabis potency reported elsewhere (ElSohly et al., 2016),  THC concentrations have both 
risen (Pijlman et al., 2005) and then subsequently declined (Niesink et al., 2015) in the 
Netherlands during the last sixteen years, providing a unique opportunity to detect similar 
changes in cannabis-related problems (Freeman and Swift, 2016). Here we sought to test 
whether changes in cannabis potency (THC) are associated with rates of first-time cannabis 
admissions to specialist drug treatment in the Netherlands from 2000-2015. This study was 
reported according to the STROBE (strengthening the reporting of observational studies in 
epidemiology) statement.  
Methods 
We combined two national sixteen-year datasets to examine whether there are time-
dependent associations between annual estimates of cannabis potency, and the number of 
first-time cannabis admissions to drug treatment. 
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Cannabis potency 
In the Netherlands, cultivation of cannabis plants is a criminal offence. However the 
government officially condones the sale of cannabis from ‘coffee shops’ under strict 
conditions (Monshouwer et al., 2011). Coffee shops are estimated to account for >70% of 
cannabis sales in the Netherlands (Wouters and Korf, 2009). Since 2000, the Trimbos 
Institute has conducted anonymous test purchases from a random selection of these coffee 
shops (50 outlets each year plus reserves) to monitor changes in potency (Niesink et al., 
2015, Pijlman et al., 2005). Purchases were conducted in January each year to control for 
seasonal variation, and immediately sent for analysis (maximum storage time three weeks at 
ambient temperature). Delta-9-Tetrahydrocannabidiol (THC), cannabidiol (CBD) and 
cannabinol (CBN) concentrations were extracted using capillary gas chromatography with 
flame ionisation detection.  All analysis took place at DeltaLab (the Netherlands) using 
standardized, internally audited and externally cross-validated methods. Further details are 
provided elsewhere (Niesink et al., 2015, Pijlman et al., 2005).  
Four different cannabis products were purchased from each retail outlet as part of the 
standardised protocol. Therefore, the number of samples collected for each type did not 
necessarily reflect their overall prevalence at retail outlets. For this reason, we did not 
combine data across all cannabis types, as the number of samples for each type could have 
biased our estimates of national cannabis potency. However, randomised sampling across 
successive years provided a reliable measure of change within individual cannabis products. 
Therefore, in order to provide the most reliable and valid estimates of national cannabis 
potency, we used data from a single product, purchases of the most popular variety of 
domestically grown herbal cannabis (‘Nederwiet’) sold at each coffee shop. This variety of 
cannabis was chosen as it is by far the most commonly consumed cannabis product in the 
Netherlands (Niesink et al., 2015, Schubart et al., 2011, van der Pol et al., 2013b, Van Laar et 
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al., 2016). Nederwiet is a Dutch term for high-potency, indoor grown herbal cannabis. It is 
sometimes referred to as ‘sinsemilla’ or ‘skunk’ and is also the most common type of 
cannabis in the  UK (Freeman et al., 2014, Potter et al., 2008) USA (ElSohly et al., 2016) and 
Australia (Swift et al., 2013). 
 
First-time admissions to drug treatment 
First-time admissions to specialist drug treatment can be used as a proxy for problematic drug 
use within a given region (UNODC, 2016) and offer a valid indicator of changes in burden 
and morbidity attributable to a particular substance. Since 1994, all Dutch drug treatment data 
(inpatient, outpatient, rehabilitation) have been compiled into the National Alcohol and Drugs 
Information System (LADIS) database, on behalf of the Ministry of Health, Welfare and 
Sports (Wisselink et al., 2016). Institutions for addiction care and addiction care 
rehabilitation provide complete data to Stichting Informatievoorziening Zorg (IVZ) on an 
annual basis, and the database is internally audited. Each client is identified through a unique 
pseudonym identification code to prevent duplicate cases. For the purposes of this study, 
annual data (2000-2015) were compiled for the following: 
(1) The number of first-time admissions with cannabis as the primary drug.  
(2) Mean age and sex of first-time admissions with cannabis as the primary drug. 
(3) The number of first-time non-cannabis admissions: primary problems with other 
drugs (alcohol, opiates, cocaine, amphetamine, and ecstasy), after excluding any 
clients with a secondary cannabis problem. 
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Data for (1) and (3) were normalised to the annual national population (Central Statistical 
Office, the Netherlands) and expressed as the number of people per 100,000 inhabitants (total 
population), in line with previous analysis of Dutch drug treatment data (Brunt et al., 2010). 
 
Statistical analysis 
Statistical analyses were conducted using STATA/SE 14. Among European clients entering 
specialist drug treatment for cannabis, the mean age of first cannabis use is 16, and the mean 
age of first treatment entry is 26 (EMCDDA, 2016). Using this 10-year lag as a normative 
window of biological plausibility, we tested associations between THC and first-time 
cannabis admissions at candidate time lags of 0-10 years. Due to evidence of autocorrelation 
in linear regression models, we conducted linear mixed effects models with THC as a fixed 
effect, and calendar year (Year) as a random effect, with first-time cannabis admissions as the 
outcome variable. Each of the individual cannabis samples were entered as separate data 
points for THC concentration, and Year (2000-2015) was coded as 0-15.  Separate models 
were tested at each candidate time lag using maximum likelihood estimation. A Bonferroni 
correction was applied to each of these 11 time-lagged models, resulting in an adjusted α 
threshold of 0.0045. As each candidate time lag had a different number of observations 
(fewer as the lag increased), comparisons between different time lags were was based upon 
the magnitude of the unstandardized regression coefficient (i.e. the strength of the association 
between THC and first-time treatment admissions) rather than the significance level. In order 
to investigate the impact of adjusting for relevant confounds, these were added as fixed 
effects to the aforementioned models. There were no missing data. 
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Results 
Cannabis potency and drug treatment 
THC concentrations were available for 969 unique cannabis samples from 2000-2015. The 
mean number of samples purchased each year was 60.56 (range: 53-66). THC increased from 
2000-2015. As shown in Figure 1, this reflected an initial increase from 8.62 (7.97, 9.27) to 
20.38 (19.09, 21.67) from 2000-2004. Thereafter, THC decreased to 15.31 (14.24, 16.38) in 
2015.  The number of first-time cannabis admissions (per 100,000 inhabitants) also increased 
from 2000-2015. As shown in Figure 1, there was an initial increase of 7.08 to 26.36 from 
2000-2010. This was followed by a decrease to 19.82 from 2010-2015 (Figure 1).  
<FIGURE 1> 
Time-dependent associations between cannabis potency and drug treatment 
Positive associations were found between THC and first-time cannabis admissions at time 
lags ranging from 0 to 9 years, with the strongest relationship at a 5-year lag, as shown in 
Table 1 (Model 1, unadjusted), b=0.370 (0.317, 0.424), p<0.0001. These findings are 
consistent with the possibility that cannabis potency may have contributed to first-time 
cannabis admissions in a time-dependent manner. Based on these estimates, each 1% increase 
in THC was associated with a 0.370 (0.317, 0.424) rise in first-time admissions per 100,000 
inhabitants. This equates to an estimated 60.765 (52.061, 69.633) people in the Netherlands 
based on the mean population between 2000 and 2015.   
 
<TABLE 1> 
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Testing alternative explanations 
First-time cannabis admissions were negatively associated with clients’ age at treatment entry 
(Supplementary Figure 1) and negatively associated with male sex (Supplementary Figure 2). 
Adjusting for age and sex attenuated the positive associations between THC and first-time 
treatment entry. However they remained significant at time lags of 0 years and 4-7 years, 
Table 1 (Model 2, adjusted for age and sex). The strongest relationship was found at a 5-year 
lag. 
Previous research suggests that CBD may offset some of the harmful effects of THC (Colizzi 
and Bhattacharyya, 2017, Englund et al., 2017). Moreover, levels of CBN in cannabis can 
provide an indicator of THC degradation following extended sample storage (Sevigny, 2013). 
However, as is typical for this type of cannabis (Nederwiet; domestically grown herbal 
cannabis), mean (95% CI) concentrations were high for THC, 15.55 (15.26, 15.85) but 
extremely low or absent for CBD, 0.30 (0.27, 0.34) and CBN, 0.14 (0.13, 0.16). CBD and 
CBN concentrations were therefore not included as covariates (Supplementary Figure 3).  
 
Prevalence of cannabis use provides an alternative explanation for changes in first-time 
cannabis admissions. We extracted data from the Dutch school survey (age 12-16), which 
were available from 1999, 2003, 2007, 2011 and 2015. Prevalence estimates for last month 
cannabis use decreased from 8.5% in 1999 through to 4.9% in 2015, and a linear model 
showed very strong fit to the data (R2 = 0.97). Data were also available for adults (age 15-64) 
from 2001, 2005, 2009, 2014 and 2015. Estimated prevalence of last month use increased 
from 3.4% to 5.3% in 2015. A linear model again showed very strong fit to the data (R2 = 
0.85). On the basis of the prevalence data available, these linear trends are unlikely to explain 
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the non-linear changes in first-time cannabis admissions, and therefore were not included as 
covariates (Supplementary Figure 4). 
 
Next, in order to account for changes common to drug treatment in general, we extracted data 
for all non-cannabis admissions (first-time admissions of alcohol, opiates, cocaine, 
amphetamines, ecstasy), after excluding any clients with cannabis as a secondary problem 
(Supplementary Figure 5). Adjusting for non-cannabis admissions (in addition to age and 
sex) further attenuated positive associations between THC and cannabis admissions. 
Significant associations remained at lags of 5-7 years, as show in Table 1 (Model 3, adjusted 
for age, sex and non-cannabis admissions). The strongest relationship was found at a 5-year 
lag, b=0.082 (0.052, 0.111), p<0.0001.  Based on these estimates, each 1% increase in THC 
was associated with a 0.082 (0.052, 0.111) rise in first-time admissions per 100,000 
inhabitants. This equates to an estimated 13.467 (8.540, 18.229) people in the Netherlands 
based on the mean population between 2000 and 2015.  The level of attenuation was similar 
when we adjusted for specific drugs showing the most similar profile to cannabis on the basis 
of raw data (Supplementary Figure 6) and change from baseline (Supplementary Figure 7). 
As shown in Supplementary Table 1, positive associations between THC and cannabis 
admissions remained significant at lags of 5-7 years after adjusting for age, sex and alcohol 
admissions (Model 3b) as well as age, sex and amphetamine admissions (Model 3c). In both 
of these models, the strongest association was again found at a 5-year lag. 
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Discussion 
Cannabis potency continues to rise in a number of states and countries (Cascini et al., 2012, 
ElSohly et al., 2016, Potter et al., 2008, Smart et al., 2017). Meanwhile, cannabis problems 
now account for a substantial and increasing number of admissions to specialist drug 
treatment worldwide (EMCDDA, 2016, UNODC, 2016). National estimates of domestic 
herbal cannabis potency (THC) and first-time cannabis admissions to drug treatment showed 
matching profiles of change (sharp rise followed by gradual decline) in the Netherlands from 
2000-2015. Using mixed effects linear regression models, we found time-dependent 
associations between THC and first-time treatment entry at lags of 0-9 years, with the 
strongest association at 5 years. These time lags are biologically plausible because they occur 
within the normative duration (10 years) between first trying cannabis and first-time entry to 
European drug treatment (EMCDDA, 2016) in which effects of cannabis potency are most 
likely to occur. These associations were attenuated after adjusting for client demographics 
and non-cannabis admissions, although positive associations remained statistically significant 
at lags of 5-7 years and were again strongest at 5 years. To our knowledge, this is the first 
study to investigate associations between changes in cannabis potency and health-related 
outcomes. 
 
Since 2000, cannabis has become the primary illicit drug responsible for first-time 
admissions to specialist drug treatment, superseding opiates and cocaine. These trends have 
been evident in several countries including the Netherlands, but also across Europe as a 
whole (EMCDDA, 2016). A recent analysis of data submitted to the European Monitoring 
Centre for Drugs and Drug Addiction (EMCDDA) (Montanari et al., 2017) found evidence 
for increasing cannabis admissions across 16 of the 22 countries examined. The authors 
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speculated that these changes could be due to several factors, including an increase in 
cannabis use, cannabis potency, and changes in drug treatment services (Montanari et al., 
2017). Our findings provide novel insight into these potential explanations. 
 
Changes in cannabis potency (but not prevalence of use, based on the available data), offers a 
potential explanation for these trends in the Netherlands between 2000 and 2015. Our 
findings add to existing evidence for a relationship between cannabis potency and poorer 
mental health and addiction outcomes (Chan et al., 2017, Di Forti et al., 2015, Freeman and 
Winstock, 2015, Meier, 2017, Schoeler et al., 2016). They also highlight the extent to which 
potency can fluctuate over time within a single cannabis product (high-potency domestic 
herbal cannabis), which is the most common type available in the Netherlands (Niesink et al., 
2015, Schubart et al., 2011, van der Pol et al., 2013b, Van Laar et al., 2016) UK (Freeman et 
al., 2014, Potter et al., 2008) USA (ElSohly et al., 2016) and Australia (Swift et al., 2013). 
This suggests that clinicians working with cannabis problems should not rely on classification 
of cannabis type alone to assess cannabinoid exposure and possible consequences of use. 
These data were collected in a single geographical region, and improved global monitoring of 
cannabis potency and health-related outcomes may be necessary to investigate these 
associations elsewhere (Freeman and Swift, 2016). However, our findings highlight a cause 
for concern regarding the health impact of extremely potent cannabis concentrates (~70% 
THC) which have very recently risen in popularity in some parts of the United States (Smart 
et al., 2017). In a rapidly changing cannabis climate, it is essential that policy makers 
consider the effects of new legislation on cannabis potency and the incidence of cannabis-
related harms.  
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If cannabis potency does contribute to drug treatment admissions (which cannot be 
established on the basis of this single observational study), our finding that the strongest 
association occurred at 5 years (extending to 7 years in fully adjusted models) suggests that 
this effect occurs at a mid-early stage in cannabis use trajectories. On the basis of these time 
lags, a typical client who started using cannabis at 16 and first entered treatment at 26 might 
be especially susceptible to variation in potency between the ages of 19-21. This could 
potentially reflect the timing of transition to cannabis use disorder in a typical user (Behrendt 
et al., 2009). However, cannabis use trajectories are likely to vary substantially across 
individuals, and may oscillate between periods of daily or occasional use. Previous research 
indicates that the association between degree of cannabis use and cannabis use disorders is 
stronger in younger people (Courtney et al., 2017). This may be in part due to age-related 
differences in sensitivity to THC (Mokrysz et al., 2016). Moreover, inexperienced cannabis 
users may be especially vulnerable to changes in potency due to their lack of tolerance 
(D'Souza et al., 2008) and inability to estimate the potency of their own cannabis (Freeman et 
al., 2014). Long-term prospective cohort studies are needed to investigate these issues 
further. One previous study employing a comprehensive set of cannabis exposure variables, 
including potency, found no relationship between cannabis use variables and three-year 
incidence of DSM-IV-TR cannabis dependence (van der Pol et al., 2013a). However, all 
participants were (near) daily users at baseline. It is therefore possible that variation in 
cannabis exposure is only associated with transition to dependence in younger and/or less 
experienced users, such as during adolescence (Silins et al., 2014). 
 
Although our data are consistent with the possibility that cannabis potency may have 
contributed to first-time cannabis admissions, the strength of association after adjustment 
suggests that other factors are also important. For example, there was a transient (one year) 
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rise in treatment admissions for all drugs in 2007 (although cannabis admissions continued 
rising to 2010). Moreover, both cannabis and non-cannabis admissions decreased between 
2013 and 2015. This could be attributable to the introduction of three-tier stepped care from 
January 2014, resulting in fewer people in addiction care being registered by the National 
Alcohol and Drugs Information System database (EMCDDA, 2014). Increases in cannabis 
admissions were also associated with a decline in the proportion of treatment seekers who 
were male, as well as a reduction in their age at treatment entry. These changes could be due 
to treatment-seeking or referral practices resulting in the admission of new clients 
independently of cannabis exposure, and/or other factors (such as rising cannabis potency) 
increasing problematic use in people who would not otherwise present to treatment services 
(i.e. younger and/or female clients). 
 
This study had several strengths. Sixteen years of annual national data were available for 
cannabis potency, obtained through randomised sampling at the retail level, and quantitative 
analysis of key cannabinoids using internally audited and cross-validated laboratory methods. 
To our knowledge, these are the highest quality data available on long-term national trends in 
cannabis potency worldwide. The rise and fall of cannabis potency within the study period 
provide a unique opportunity to detect time-dependent associations in cannabis-related health 
outcomes. Official tolerance of cannabis use in the Netherlands minimises confounding 
influences of the criminal justice system and/or stigma. National drug treatment data provide 
a valid indicator of changes in burden and morbidity attributable to a particular substance, 
and were available annually from an internally-audited database. However, a key limitation is 
that these datasets were not linked at the individual level. Furthermore, data were not 
available at monthly or quarterly intervals, which could have improved the precision of 
statistical modelling. Prospective cohort data, using a comprehensive assessment of cannabis 
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exposure including cannabis type (van der Pol et al., 2013a) could allow associations to be 
tested within individuals and permit adjustment for other relevant confounds that could not be 
addressed in this study. However, data on cannabis potency is extremely rare in existing 
cohorts and we are unaware of any studies that have quantified THC concentrations in 
cannabis from the same individuals repeatedly over time. In order to provide the most reliable 
and valid estimates of users’ exposure to variation in cannabis potency, we analysed samples 
of the most popular form of cannabis sold in the Netherlands (Niesink et al., 2015, Schubart 
et al., 2011, van der Pol et al., 2013b, Van Laar et al., 2016). We cannot exclude the 
possibility that any effects of potency might have been driven by use of other types of 
cannabis. However, similar trends in potency have been reported for other cannabis products 
over the same time period (Niesink et al., 2015, Pijlman et al., 2005) with no evidence for a 
product by time interaction (Niesink et al., 2015). Prevalence data were available for both 
adolescent and adult cannabis use in the last month. However, these were not collected 
annually and were not linked to outcomes at the population level. This limits the extent to 
which prevalence can be excluded as a possible explanation for trends in cannabis treatment. 
However, the same (lack of) relationship has also been observed in other countries with 
annual data such as the UK, where prevalence of cannabis use has decreased, but potency and 
treatment admissions have both risen (Freeman and Winstock, 2015).  
 
In conclusion, this sixteen-year observational study found positive associations between 
changes in cannabis potency and first-time cannabis admissions to specialist drug treatment. 
After adjusting for other drug treatment admissions and client demographics, these 
associations were attenuated but remained statistically significant at 5-7 year time lags. The 
strongest association, both before and after adjustment, was at 5 years. Our findings have 
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relevance in the context of rising cannabis potency, increased demand for cannabis treatment, 
and global policy reform. 
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Table 1: Unstandardised regression coefficients (95% CIs) for associations between delta-9-tetrahydrocannabinol (THC) concentrations 
in domestic herbal cannabis and first-time cannabis admissions to drug treatment, at time lags of 0-10 years. Estimates are presented 
unadjusted (Model 1), adjusted for age and sex 
(Model 2), and adjusted for age, sex and first-time non-cannabis admissions (Model 3) 
 
 
 
 
 
 
 
 
Figure 1: Mean (95% CI) concentrations of delta-9-tetrahydrocannabinol (THC) in domestic herbal cannabis and first-time cannabis 
admissions to specialist drug treatment (per 100,000 inhabitants) from 2000-2015  
 
Lag 
 Model 1  
(unadjusted) 
Model 2  
(adjusted for age and sex) 
Model 3  
(adjusted for age, sex and non-cannabis admissions) 
(years) df b 95% CI z p b 95% CI z p b 95% CI z p 
0 1, 969 0.075 (0.028, 0.123) 3.113 0.0018 0.067 (0.041 0.092) 5.182 <0.0001 0.013 (-0.007 0.033) 1.300 0.1937 
1 1, 909 0.139 (0.090, 0.189) 5.528 <0.0001 -0.054  (-0.078 -0.030) -4.387 <0.0001 -0.039 (-0.061 -0.018) -3.638 0.0003 
2 1, 843 0.169 (0.118, 0.220) 6.514 <0.0001 -0.013 (-0.039 0.012) -1.007 0.3140 -0.015 (-0.038 0.007) -1.324 0.1856 
3 1, 782 0.238 (0.185, 0.290) 8.895 <0.0001 0.015 (-0.014 0.044) 1.008 0.3136 -0.028 (-0.054 -0.002) -2.142 0.0322 
4 1, 724 0.287 (0.233, 0.341) 10.381 <0.0001 0.042 (0.012 0.072) 2.768 0.0056 0.014 (-0.013 0.041) 1.021 0.3073 
5 1, 659 0.370 (0.317, 0.424) 13.666 <0.0001 0.095 (0.063 0.128) 5.793 <0.0001 0.082 (0.052 0.111) 5.428 <0.0001 
6 1, 593 0.335 (0.289, 0.380) 14.450 <0.0001 0.051 (0.030 0.072) 4.719 <0.0001 0.037 (0.015 0.059) 3.286 0.0010 
7 1, 537 0.213 (0.181, 0.245) 13.053 <0.0001 0.039 (0.018 0.061) 3.601 0.0003 0.044 (0.023 0.064) 4.213 <0.0001 
8 1, 477 0.122 (0.089, 0.155) 7.237 <0.0001 -0.028 (-0.052 -0.004) -2.245 0.0248 0.005 (-0.013 0.023) 0.581 0.5616 
9 1, 424 0.094 (0.064, 0.123) 6.189 <0.0001 0.014 (-0.014 0.041) 0.980 0.3272 -0.000 (-0.018 0.018) -0.025 0.9802 
10 1, 366 0.017 (-0.009, 0.044) 1.274 0.2027 -0.027 (-0.051 -0.002) -2.160 0.0308 -0.006 (-0.010 -0.002) -2.767 0.0057 
